Format

Send to

Choose Destination
Circ Heart Fail. 2018 Dec;11(12):e005276. doi: 10.1161/CIRCHEARTFAILURE.118.005276.

Current Use of Hearts From Hepatitis C Viremic Donors.

Author information

1
Division of Cardiovascular Medicine, Heart Transplantation, Stanford University, Palo Alto, CA (Y.M., J.J.T., K.K.K.).
2
Ted Rogers Centre of Excellence in Heart Function, Peter Munk Cardiac Centre, University Health Network, Department of Medicine, University of Toronto, Canada (Y.M., C.P.S.F., C.M., H.J.R.).
3
Toronto Centre for Liver Disease, University Health Network, Department of Medicine, University of Toronto, ON, Canada (A.F.G.).

Abstract

BACKGROUND:

Strategies to improve donor heart utilization are required in the setting of limited donor availability. One innovative strategy is to consider the use of hepatitis C viremic (HCV) nucleic acid amplification test positive donors in hepatitis C-negative recipients, given the availability of highly effective direct acting antiviral agents. We utilized United Network for Organ Sharing data to evaluate the geographic distribution, clinical characteristics, and post-transplant outcomes of HCV+ donor hearts.

METHODS AND RESULTS:

The United Network for Organ Sharing registry was queried for all HCV+ recovered donors and those considered for heart donation classified by sex, age group, United Network for Organ Sharing region, and cause of death from January 1, 2014, to December 31, 2017. Propensity score matching (3:1) was applied to the recipients based on the index for mortality prediction after cardiac transplantation score and donor risk index. A total of 1306 HCV+ donors were recovered from 2014 to 2017 of whom 1078 (82.5%) were 18 to 49 and predominantly from the Appalachia region (United Network for Organ Sharing regions 2, 3, and 11). A total of 64 (5%) HCV+ donor hearts were transplanted in this interval. The match-adjusted risk difference in survival was estimated to be 0.87% ( P=0.83) at 12 months.

CONCLUSIONS:

To meet the demands of heart transplantation, we must consider additional strategies to expand the donor pool. From 2014 to 2017, despite availability of highly effective direct acting antiviral therapy, only 5% of HCV+ donor hearts were accepted for transplantation. National efforts may be required to capitalize on this resource while we continue to carefully monitor the safety of this novel approach.

KEYWORDS:

cause of death; heart transplantation; hepacivirus; hepatitis C; propensity score; survival; tissue donors

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center